var data={"title":"Hyaluronidase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hyaluronidase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6317?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hyaluronidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hyaluronidase: Patient drug information&quot;</a> and <a href=\"topic.htm?path=hyaluronidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hyaluronidase: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179308\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amphadase;</li>\n      <li>Hylenex;</li>\n      <li>Vitrase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179341\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote, Extravasation;</li>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179310\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin test:</b> Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20-30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dehydration:</b> <i>Hypodermoclysis:</i> SubQ: 150 or 200 units followed by subcutaneous isotonic fluid administration &ge;1000 mL <b>or</b> may be added to small volumes (&le;200 mL) of subcutaneous replacement fluid. Rate and volume of a single clysis should not exceed those used for infusion of IV fluids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dispersion/absorption enhancement of injected drugs:</b> SubQ: 50-300 units (usual dose: 150 units) either injected prior to drug administration or added to injection solution (consult compatibility reference prior to mixing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation management (off-label use):</b> <b>Note:</b> Administer as soon as extravasation is recognized. Do not use for extravasation of vasoconstrictors (eg, dopamine, norepinephrine [manage with phentolamine]). For extravasation management, skin testing is not necessary prior to use. The concentration of doses used to manage extravasation ranges from <b>15 units/mL to 150 units/mL</b>; refer to specific vesicant (below) for a description of doses/concentrations used in published case reports and/or reviews:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Aminophylline, calcium solutions, dextrose 10%, nafcillin, parenteral nutrition/amino acid (4.25%</i>\n      <i>), potassium solutions, radiocontrast media extravasation, and sodium chloride (&gt;1%):</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983, Reynolds 2014, Zenk 1981b).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Contrast media extravasation: The injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dextrose 50% extravasation:</i> Injection of a total of 1 mL (150 units/mL) as five separate 0.2 mL injections administered along the leading edge of erythema has also been used successfully for dextrose 50% extravasation (Wiegand 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mannitol:</i> SubQ: Administer multiple injections of 0.5 to 1 mL (15 units/mL) around the periphery of the extravasation (Kumar 2003) <b>or</b> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Paclitaxel:</i> IV: Administer 1 to 6 mL (150 units/mL) into existing IV line, and/or, if needle/cannula has been removed, inject subcutaneously in a clockwise manner around area of extravasation. Usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug; may repeat several times over the next 3 to 4 hours (Ener 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sodium bicarbonate: </i>SubQ: Administer 4 to 5 separate 0.2 mL injections (15 units/mL) around area of extravasation (Hurst 2004) <b>or</b> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vinca alkaloid (vinblastine, vincristine, vindesine, vinorelbine) extravasation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If needle/cannula still in place: IV: After gently aspirating to remove extravasated vesicant, administer 1 to 6 mL hyaluronidase (150 units/mL) into existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo 2012, Schulmeister 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If needle/cannula has been removed: SubQ: Inject 1 to 6 mL (150 units/mL) in a clock wise manner using 1 mL for every 1 mL of drug extravasated (Schulmeister 2011) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) into the extravasation site (Polovich 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Retrobulbar/peribulbar block (adjuvant in bupivacaine-lidocaine mixture) (off-label use):</b> 3.75 units (150 units/mL concentration) or 7.5 units (150 units/mL concentration) for every 1 mL of a 1:1 mixture of bupivacaine 0.75% and lidocaine 2%; administer a total of 6 to 8 mL of mixture divided evenly between retrobulbar and peribulbar injections (Kallio 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179326\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hyaluronidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hyaluronidase: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Skin test:</b> Children and Adolescents: Intradermal: 0.02 mL (Amphadase 3 units, Hylenex 3 units, or Vitrase 4 units) of a 150 units/mL (Amphadase, Hylenex) or 200 units/mL (Vitrase) solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20-30 minutes with localized itching (transient erythema is not considered a positive reaction). Skin testing is not necessary prior to use for extravasation management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dehydration:</b> Hypodermoclysis: SubQ: 150 or 200 units followed by subcutaneous isotonic fluid administration &ge;1000 mL <b>or</b> may be added to small volumes (&le;200 mL) of subcutaneous replacement fluid  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premature Infants: Volume of a single clysis/day should not exceed 25 mL/kg and the rate of administration should not exceed 2 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &lt;3 years: Volume of a single clysis should not exceed 200 mL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;3 years and Adolescents: Rate and volume of a single clysis should not exceed those used for infusion of IV fluids </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dispersion/absorption enhancement of injected drugs:</b> Children and Adolescents: SubQ: 50-300 units (usual dose: 150 units) either injected prior to drug administration or added to injection solution (consult compatibility reference prior to mixing)   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Subcutaneous urography:</b> Infants and Children: SubQ: 75 units over each scapula followed by injection of contrast medium at the same site; patient should be in the prone position during drug administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179311\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897525\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897526\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179291\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amphadase: 150 units/mL (1 mL) [contains edetate disodium, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hylenex: 150 units/mL (1 mL [DSC]) [contains albumin human, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hylenex: 150 units/mL (1 mL) [contains albumin human, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitrase: 200 units/mL (1.2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 units/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179294\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Do <b>not</b> administer IV for labeled uses (enzyme is rapidly inactivated and desired effects will not be produced).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management (off-label use):</b> Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line). Keep needle/cannula in place for vinca alkaloid extravasation, if appropriate, remove needle/cannula for other vesicants; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local administration (intradermal or subQ): Using a 150 units/mL concentration, mix 0.1 mL (of 150 units/mL) with 0.9 mL NS in 1 mL syringe to make final concentration of 15 units/mL; administer a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL intradermally and/or subcutaneously into area of extravasation (MacCara 1983, Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vinca alkaloids: If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo 2012, Schulmeister 2011). If needle/cannula has been removed, inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for 1 mL of drug extravasated (Schulmeister 2011) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (25-gauge needle) subcutaneously into the extravasation site (Polovich 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retrobulbar/peribulbar administration (off-label use): After combining hyaluronidase with a 1:1 mixture of bupivacaine 0.75% and lidocaine 2%, administer according to standard anesthetic technique (Kallio 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179293\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Absorption and dispersion of injected drugs:</b> As an adjuvant to increase the absorption and dispersion of other injected drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subcutaneous fluid administration:</b> As an adjuvant in subcutaneous fluid administration (hypodermoclysis) for achieving hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subcutaneous urography:</b> As an adjunct in subcutaneous urography for improving resorption of radiopaque agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474801\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Extravasation management; Local anesthetic adjuvant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179284\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic-like reactions (retrobulbar block or IV injections), anaphylaxis, angioedema, hypersensitivity reaction, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179297\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to hyaluronidase or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179281\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Use with caution in patients with reported history of bee sting allergy; hyaluronidase is an active component in bee venom (Lee 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sensitization: Discontinue if sensitization occurs (a skin test may be performed to determine hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some products may contain albumin; albumin carries an extremely remote risk for transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD). No cases of transmission of viral diseases, CJD, or vCJD have been identified for licensed albumin or albumin contained in other licensed products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For labeled indications, do not administer intravenously (enzyme is rapidly inactivated and desired effects will not be produced); do not inject in or around infected or inflamed areas; may spread localized infection. Do not apply directly to the cornea; not for topical use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Ineffective for extravasation management of vasoconstrictors (eg, dopamine, epinephrine, norepinephrine, phenylephrine, vasopressin) or to reduce swelling of bites or stings; do not use in these settings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299453\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179286\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8657&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<b> Exceptions: </b>EPINEPHrine (Nasal); EPINEPHrine (Oral Inhalation); Isometheptene; Pseudoephedrine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<b> Exceptions: </b>Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Hydrocortisone (Ophthalmic); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Hyaluronidase may enhance the adverse/toxic effect of DOPamine.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179288\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies (not conducted with all products). Administration during labor did not cause any increase in blood loss or differences in cervical trauma. It is not known whether it affects the fetus if used during labor. Hyaluronidase has been evaluated for use prior to intracytoplasmic sperm injection (ICSI) to increase male fertility (DeVos 2008; Evison 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570919\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if hyaluronidase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering hyaluronidase to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20138924\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Extravasation management (off-label use): Document and monitor extravasation site.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179280\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Enzymatically modifies the permeability of connective tissue through hydrolysis of hyaluronic acid, one of the chief components of tissue cement which offers resistance to diffusion of liquids through tissues; hyaluronidase increases the distribution/dispersion and absorption of locally injected or extravasated substances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179296\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: SubQ: Immediate; when used for extravasation, there is usually a reduction in swelling within 15 to 30 minutes after administration (Zenk 1981b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 24 to 48 hours (variable)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5164759\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amphadase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 units/mL (1 mL): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hylenex Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 units/mL (1 mL): $66.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vitrase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (1.2 mL): $112.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038653\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Facidase (IN);</li>\n      <li>H-lase (KR);</li>\n      <li>Hyalase (AU, BB, BH, BM, BS, BZ, CY, GR, GY, IL, JM, MT, NZ, PR, SG, SR, TR, TT, ZA);</li>\n      <li>Hyalasedessau (KR);</li>\n      <li>Hyalozima (BR);</li>\n      <li>Hyaluronidase Choay (FR);</li>\n      <li>Hyanid (BD);</li>\n      <li>Hyase (HN);</li>\n      <li>Hyason (NL);</li>\n      <li>Hyfresh (QA);</li>\n      <li>Hylase (AT, BG, CZ, DE, PL, VN);</li>\n      <li>Hylorase (IN);</li>\n      <li>Hynidase (ET, IN);</li>\n      <li>Jaluran (IT);</li>\n      <li>Lasonil (PT);</li>\n      <li>Longidaza (RU);</li>\n      <li>Lydase (RU, UA);</li>\n      <li>Lyrase (RU);</li>\n      <li>Malinda (KR);</li>\n      <li>Nydase (RU);</li>\n      <li>Penetrase (DK);</li>\n      <li>Permease (CH);</li>\n      <li>Sprase (JP);</li>\n      <li>Unidasa (AR, PY);</li>\n      <li>Vitrase (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Albanell J and Baselga J, &ldquo;Systemic Therapy Emergencies,&rdquo; <i>Semin Oncol</i>, 2000, 27(3):347-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/10864222/pubmed\" target=\"_blank\" id=\"10864222\">10864222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allen CH, Etzwiler LS, Miller MK, et al, &quot;Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration,&quot; <i>Pediatrics</i>, 2009, 124(5):e858-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/19805455/pubmed\" target=\"_blank\" id=\"19805455\">19805455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allen CA, Etzwiler LS, Miller MK, et al, &ldquo;Subcutaneous Hydration in Children Using Recombinant Human Hyaluronidase: Safety and Ease of Use,&rdquo; <i>Ann Emerg Med</i>, 2008, 52(4 Suppl):75-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amphadase (hyaluronidase) [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Barash.2009\"></a>Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berger EY, &ldquo;Nutrition by Hypodermoclysis,&rdquo; <i>J Am Geriatr Soc</i>, 1984, 32(3):199-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/6421919/pubmed\" target=\"_blank\" id=\"6421919\">6421919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertelli G, &ldquo;Prevention and Management of Extravasation of Cytotoxic Drugs,&rdquo; <i>Drug Saf</i>, 1995, 12(4):245-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/7646823/pubmed\" target=\"_blank\" id=\"7646823\">7646823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertelli G, Dini D, Forno GB, et al, &ldquo;Hyaluronidase as an Antidote to Extravasation of Vinca Alkaloids: Clinical Results,&rdquo; <i>J Cancer Res Clin Oncol</i>, 1994, 120(8):505-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/8207052/pubmed\" target=\"_blank\" id=\"8207052\">8207052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cochran ST, Bomyea K, and Kahn M, &ldquo;Treatment of Iodinated Contrast Material Extravasation With Hyaluronidase,&rdquo; <i>Acad Radiol</i>, 2002, 9(Suppl 2):544-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connolly S, Korzemba H, Harb G, et al, &ldquo;Techniques for Hyaluronidase-Facilitated Subcutaneous Fluid Administration With Recombinant Human Hyaluronidase: The Increased Flow Utilizing Subcutaneously Enabled Administration Technique (INFUSE AT) Study,&rdquo; <i>J Infus Nurs</i>, 2011, 34(5):300-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/21915003/pubmed\" target=\"_blank\" id=\"21915003\">21915003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Wit M, Ortner P, Lipp HP, et al, &quot;Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment,&quot; <i>Onkologie</i>, 2013, 36(3):127-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/23486002/pubmed\" target=\"_blank\" id=\"23486002\">23486002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Vos A, Van Landuyt L, Van Ranst H, et al, &quot;Randomized Sibling-Oocyte Study Using Recombinant Human Hyaluronidase versus Bovine-Derived Sigma Hyaluronidase in ICSI Patients,&quot; <i>Hum Reprod</i>, 2008, 23(8):1815-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/18540008/pubmed\" target=\"_blank\" id=\"18540008\">18540008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dorr RT, &ldquo;Vinca Alkaloid Ulceration: Experimental Mouse Model and Effects of Local Antidotes,&rdquo; <i>Proc Am Soc Clin Oncol</i>, 1982, 1:428.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elam EA, Dorr RT, Lagel KE, et al, &ldquo;Cutaneous Ulceration Due to Contrast Extravasation. Experimental Assessment of Injury and Potential Antidotes,&rdquo; <i>Invest Radiol</i>, 1991, 26(1):13-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/2022447/pubmed\" target=\"_blank\" id=\"2022447\">2022447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ener RA, Meglathery SB, and Styler M, &quot;Extravasation of Systemic Hemato-Oncological Therapies,&quot; <i>Ann Oncol</i>, 2004, 15(6):858-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/15151940/pubmed\" target=\"_blank\" id=\"15151940\">15151940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evison M, Pretty C, Taylor E, et al, &quot;Human Recombinant Hyaluronidase (Cumulase) Improves Intracytoplasmic Sperm Injection Survival and Fertilization Rates,&quot; <i>Reprod Biomed Online,</i> 2009, 18(6):811-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/19490785/pubmed\" target=\"_blank\" id=\"19490785\">19490785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hannon MG and Lee SK, &ldquo;Extravasation Injuries,&rdquo; <i>J Hand Surg Am</i>, 2011, 36(12):2060-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/22123049/pubmed\" target=\"_blank\" id=\"22123049\">22123049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrold K, Gould D, Drey N, &quot;The Efficacy of Saline Washout Technique in the Management of Exfoliant and Vesicant Chemotherapy Extravasation: A Historical Case Series Report,&quot; <i>Eur J Cancer Care (Engl)</i>, 2013, 22(2):169-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/23320981/pubmed\" target=\"_blank\" id=\"23320981\">23320981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hylenex (hyaluronidase injection recombinant human) [prescribing information]. San Diego, CA: Halozyme Therapeutics; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11004052\"></a>Kallio H, Paloheimo M, and Maunuksela EL, &ldquo;Hyaluronidase as an Adjuvant in Bupivacaine-Lidocaine Mixture for Retrobulbar/Peribulbar Block,&rdquo; <i>Anesth Analg</i>, 2000, 91(4):934-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/11004052/pubmed\" target=\"_blank\" id=\"11004052\">11004052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14500188\"></a>Kumar MM and Sprung J, &ldquo;The Use of Hyaluronidase to Treat Mannitol Extravasation,&rdquo; <i>Anesth Analg</i>, 2003, 97(4):1199-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/14500188/pubmed\" target=\"_blank\" id=\"14500188\">14500188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12644428\"></a>Lai F, Sutton B, Nicholson G. Comparison of L-bupivacaine 0.75% and lidocaine 2% with bupivacaine 0.75% and lidocaine 2% for peribulbar anaesthesia. <i>Br J Anaesth</i>. 2003;90(4):512-514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/12644428/pubmed\" target=\"_blank\" id=\"12644428\">12644428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Grummer SE, Kriegel D, et al. <i>Hyaluronidase</i>. Dermatol Surg. 2010;36(7):1071-1077.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/20482727/pubmed\" target=\"_blank\" id=\"20482727\">20482727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipschitz S, Campbell AJ, Roberts MS, et al, &ldquo;Subcutaneous Fluid Administration in Elderly Subjects: Validation of an Underused Technique,&rdquo; <i>J Am Geriatr Soc</i>, 1991, 39(1):6-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/1846157/pubmed\" target=\"_blank\" id=\"1846157\">1846157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6628223\"></a>MacCara ME, &ldquo;Extravasation - A Hazard of Intravenous Therapy,&rdquo; <i>Drug Intell Clin Pharm</i>, 1983, 17:713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12027856\"></a>Moharib MM, Mitra S, Rizvi SG. Effect of alkalinization and/or hyaluronidase adjuvancy on a local anesthetic mixture for sub-Tenon's ophthalmic block. <i>Acta Anaesthesiol Scand</i>. 2002;46(5):599-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/12027856/pubmed\" target=\"_blank\" id=\"12027856\">12027856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8610868\"></a>Nathan N, Benrhaiem M, Lotfi H, et al. The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. <i>Anesth Analg</i>. 1996;82(5):1060-1064.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/8610868/pubmed\" target=\"_blank\" id=\"8610868\">8610868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parmegiani L, Cognigni GE, Bernardi S, et al, &quot;Comparison of Two Ready-To-Use Systems Designed for Sperm-Hyaluronic Acid Binding Selection Before Intracytoplasmic Sperm Injection: PICSI vs. Sperm Slow: A Prospective, Randomized Trial,&quot; <i>Fertil Steril</i>, 2012, 98(3):632-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/22749221/pubmed\" target=\"_blank\" id=\"22749221\">22749221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22997449\"></a>P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Polovich.2009\"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raszka WV Jr, Kueser TK, Smith FR, et al, &ldquo;The Use of Hyaluronidase in the Treatment of Intravenous Extravasation Injuries,&rdquo; <i>J Perinatol</i>, 19909, 10(2):146-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/2358898/pubmed\" target=\"_blank\" id=\"2358898\">2358898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22633726\"></a>Rowlett J, &ldquo;Extravasation of Contrast Media Managed With Recombinant Human Hyaluronidase,&rdquo; <i>Am J Emerg Med</i>, 2012, 30(9):2102, e1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21255716\"></a>Schulmeister L, &quot;Extravasation Management: Clinical Update,&quot; <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/21255716/pubmed\" target=\"_blank\" id=\"21255716\">21255716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokol DK, Dahlmann A, and Dunn DW, &ldquo;Hyaluronidase Treatment for Intravenous Phenytoin Extravasation,&rdquo; <i>J Child Neurol</i>, 1998, 13(5):246-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/9620019/pubmed\" target=\"_blank\" id=\"9620019\">9620019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spandorfer PR, Mace SE, Okada PJ, et al, &quot;A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department,&quot; <i>Clin Ther</i>, 2012, 34(11):2232-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/23062548/pubmed\" target=\"_blank\" id=\"23062548\">23062548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11576046\"></a>van den Berg AA, Montoya-Pelaez LF. Comparison of lignocaine 2% with adrenaline, bupivacaine 0.5% with or without hyaluronidase and a mixture of bupivacaine, lignocaine and hyaluronidase for peribulbar block analgesia. <i>Acta Anaesthesiol Scand</i>. 2001;45(8):961-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/11576046/pubmed\" target=\"_blank\" id=\"11576046\">11576046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vitrase (hyaluronidase ovine) injection [prescribing information]. Irvine, CA: ISTA Pharmaceuticals Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20159411\"></a>Weigand R and Brown J, &ldquo;Hyaluronidase for the Management of Dextrose Extravasation,&rdquo; <i>Am J Emerg Med</i>, 2010, 28(2):257.e1-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/20159411/pubmed\" target=\"_blank\" id=\"20159411\">20159411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Zenk.1981.1\"></a>Zenk KE, &ldquo;Hyaluronidase: An Antidote for Intravenous Extravasations,&rdquo; <i>CSHP Voice</i>, 1981a, 66-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Zenk.1981.2\"></a>Zenk KE, &ldquo;Management of Intravenous Extravasations,&rdquo; <i>Infusion</i>, 1981b, 5:77-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE, &ldquo;Treating I.V. Extravasations With Hyaluronidase,&rdquo; <i>ASHP Signal</i>, 1986, 10:25,29.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE, Dungy CI, and Greene GR, &ldquo;Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,&rdquo; <i>Am J Dis Child</i>, 1981c, 135(12):1113-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronidase-drug-information/abstract-text/7315807/pubmed\" target=\"_blank\" id=\"7315807\">7315807</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8657 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179308\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F179341\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F179310\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F179326\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F179311\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897525\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897526\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179291\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F179278\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F179294\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F179293\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474801\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179284\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179297\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179281\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299453\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179286\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179288\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F179299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16570919\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20138924\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179280\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F179296\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5164759\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038653\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8657|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hyaluronidase-patient-drug-information\" class=\"drug drug_patient\">Hyaluronidase: Patient drug information</a></li><li><a href=\"topic.htm?path=hyaluronidase-pediatric-drug-information\" class=\"drug drug_pediatric\">Hyaluronidase: Pediatric drug information</a></li></ul></div></div>","javascript":null}